Exosomes As Biomarkers For Identification Quantitation And Stratification Of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia (CLL) is the most common type of adult leukemia in western countries. CLL is a clinically heterogeneous disease classified by different stages. Effective therapy of CLL patients relies of correct stratification according to the stage.

We developed a new method of identification of the CLL stage based on exosome markers. Using the phage display technology, we discovered 4 peptides, which specifically interact with CLL exosomes.We validated high specificity of these peptides to CLL exosomes by flow cytometry. We plan to further develop peptides that can be used for identification of CLL stages. This technology will simplify diagnostics and improve therapy outcomes.